<DOC>
	<DOCNO>NCT01133457</DOCNO>
	<brief_summary>The objective study compare single-dose relative bioavailability Dr. Reddy 's Laboratories , Ltd. Merck &amp; Co. ( Propecia® ) 1 mg finasteride tablet feed condition follow administration 3 mg dose .</brief_summary>
	<brief_title>Bioequivalence Study Dr.Reddy 's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition</brief_title>
	<detailed_description>Detailed Description : The study conduct open-label , randomize , single-dose , 2-way crossover , relative bioavailability study perform 24 healthy adult male volunteer 2 alternate . A total 24 subject complete clinical phase study . In period , subject house even dose 36-hour blood draw . Single oral 3 mg dos separate washout period 7 day .</detailed_description>
	<mesh_term>Finasteride</mesh_term>
	<criteria>History presence significant : • cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic psychiatric disease . In addition , history presence : alcoholism drug abuse within past year ; hypersensitivity idiosyncratic reaction finasteride 5a reductase inhibitor . Subjects abnormal diet ( whatever reason ) 28 day precede study . Subjects , completion study , would donate excess : 500 mL blood 14 day , 500 750 mL blood 14 day ( unless approve Principal Investigator ) , 1000 mL blood 90 day , 1250 mL blood 120 day , 1500 mL blood 180 day , 2000 mL blood 270 day , 2500 mL blood 1 year . Subjects participate another clinical trial within 28 day prior first dosing .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2002</verification_date>
	<keyword>Bioequivalence , Finasteride , Crossover</keyword>
</DOC>